Please use this identifier to cite or link to this item:
http://20.193.157.4:9595/xmlui/handle/123456789/1553Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Anitha B, Inamadar AC, Regunatha S. | - |
| dc.date.accessioned | 2020-01-02T10:12:41Z | - |
| dc.date.available | 2020-01-02T10:12:41Z | - |
| dc.date.issued | 2009-07 | - |
| dc.identifier.uri | http://hdl.handle.net/123456789/1553 | - |
| dc.description.abstract | Finasteride, a specific and competitive inhibitor of 5α-reductase enzyme Type 2, inhibits the conversion of testosterone to dihydrotestosterone (DHT). In adults, DHT acts as primary androgen in prostate and hair follicles. The only FDA-approved dermatological indication of finasteride is androgenetic alopecia. But, apprehension regarding sexual dysfunction associated with finasteride deters dermatologists from prescribing the drug and patients from taking the drug for androgenetic alopecia. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | BLDE(Deemed to be University) | en_US |
| dc.subject | Finasteride, prostate cancer, sexual function | en_US |
| dc.title | Finasteride-its impact on sexual function and prostate cancer. | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Faculty of Dermatology | |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.